Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL870939 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL870938 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27640995 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL3293375 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28107748 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28415027 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28134059 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL29777539 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27745349 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27616123 | 0.92 | LMNA (0.41) | LMNAL3MBTL1TDP1TP53PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112715802-A | Probiotic beverage capable of enhancing immunity and preparation method thereof | 李桂勇 | 2021-04-30 | — | — | CN | claimed |
| CN-109298190-B | High density lipoprotein cholesterol detect reagent box | 山东博科生物产业有限公司 | 2020-04-28 | — | — | CN | claimed |
| CN-121570554-A | Dendrobium officinale fermentation liquor composition with anti-inflammatory effect and preparation method thereof | 浙江省农业科学院 | 2026-02-27 | — | — | CN | disclosed |
| US-12331030-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) | 2025-06-17 | — | — | US | disclosed |
| CN-116549428-B | New application of 4-hydroxyisoleucine | 郑州大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-115737592-B | Nanometer preparation for treating colonitis and preparation method and application thereof | 宁夏医科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119157103-A | Construction method of over-expression MR-1 transgenic colorectal cancer model mouse | 中国医学科学院医药生物技术研究所 | 2024-12-20 | — | — | CN | disclosed |
| CN-117987533-A | Biomarker for periodontitis aggravated by inflammatory bowel disease activity and application of biomarker | 中山大学附属口腔医院 | 2024-05-07 | — | — | CN | disclosed |
| US-20240132466-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | TIANJIN HEMAY PHARMACEUTICAL SCI TECH CO LTD (CN) | 2024-04-25 | — | — | US | disclosed |
| US-11873287-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) | 2024-01-16 | — | — | US | disclosed |
| CN-117296926-A | Synbiotic rheum officinale solid beverage and preparation method and application thereof | 天津大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-112715802-A | Probiotic beverage capable of enhancing immunity and preparation method thereof | 李桂勇 | 2021-04-30 | — | — | CN | disclosed |
| CN-109298190-B | High density lipoprotein cholesterol detect reagent box | 山东博科生物产业有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-3546450-A1 | PIPERIDINE-2,6-DIONE DERIVATIVE AND TREATMENT FOR ULCERATIVE COLITIS | Tianjin Hemay Bio-Tech Co., Ltd (CN) | 2019-10-02 | — | — | EP | disclosed |
| CN-102985091-B | Use antimicrobial peptide chelate compound treatment dermatosis and abnormal compositions and method | 新科蒂斯公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-105520938-A | COMPOSITION FOR INHIBITING NADPH OXIDASE ACTIVITY | PCB ASS INC | 2016-04-27 | — | — | CN | disclosed |
| CN-1222612-C | Method of extensive culture of antigen-specific cytotoxic T cells | TAKARA SHUZO CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| CN-1192780-C | Therapeutical agent | TAKARA SHUZO CO (JP) | 2005-03-16 | — | — | CN | disclosed |
| CN-1469923-A | Method for expanding and culturing antigen specific cytotoxic T cells | �����﹤����ʽ���� | 2004-01-21 | — | — | CN | disclosed |
| CN-1355703-A | Therapeutical agent | TAKARA SHUZO CO (JP) | 2002-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132466-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | DPYD, PTGDR2, UCK2 | LMNA 4089/4885L3MBTL1 4790/4885TDP1 3996/4885 |
| US-12331030-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | DPYD, PTGDR2, UCK2 | LMNA 4089/4885L3MBTL1 4790/4885TDP1 3996/4885 |
| US-11873287-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | DPYD, PTGDR2, UCK2 | LMNA 4089/4885L3MBTL1 4790/4885TDP1 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.